JP2004529180A - ＩｇＥ関連障害を処置するのに使用するための組成物 - Google Patents

ＩｇＥ関連障害を処置するのに使用するための組成物 Download PDF

Info

Publication number
JP2004529180A
JP2004529180A JP2002589041A JP2002589041A JP2004529180A JP 2004529180 A JP2004529180 A JP 2004529180A JP 2002589041 A JP2002589041 A JP 2002589041A JP 2002589041 A JP2002589041 A JP 2002589041A JP 2004529180 A JP2004529180 A JP 2004529180A
Authority
JP
Japan
Prior art keywords
ige
composition
antigen
subject
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529180A5 (enExample
Inventor
トーマス・フルチュ
イェンス・ブラウブルガー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2004529180A publication Critical patent/JP2004529180A/ja
Publication of JP2004529180A5 publication Critical patent/JP2004529180A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002589041A 2001-05-11 2001-05-11 ＩｇＥ関連障害を処置するのに使用するための組成物 Pending JP2004529180A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/005412 WO2002092125A1 (en) 2001-05-11 2001-05-11 Compositions for use in treating ige-associated disorders

Publications (2)

Publication Number Publication Date
JP2004529180A true JP2004529180A (ja) 2004-09-24
JP2004529180A5 JP2004529180A5 (enExample) 2008-06-26

Family

ID=8164413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589041A Pending JP2004529180A (ja) 2001-05-11 2001-05-11 ＩｇＥ関連障害を処置するのに使用するための組成物

Country Status (7)

Country Link
US (1) US20050031609A1 (enExample)
EP (1) EP1390067A1 (enExample)
JP (1) JP2004529180A (enExample)
CN (1) CN1507353A (enExample)
BR (1) BR0117009A (enExample)
CA (1) CA2446108A1 (enExample)
WO (1) WO2002092125A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
KR20060096030A (ko) * 2003-09-17 2006-09-05 베이비 부스트 인코퍼레이티드 알레르기 방지 방법 및 기구
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
ATE524561T1 (de) * 2004-04-06 2011-09-15 Sinai School Medicine Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
WO2007095230A2 (en) * 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
WO2025010086A1 (en) 2023-07-05 2025-01-09 Genentech, Inc. Anti-ige antibody therapy for multiple food allergies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
AP660A (en) * 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物

Also Published As

Publication number Publication date
BR0117009A (pt) 2004-04-20
US20050031609A1 (en) 2005-02-10
EP1390067A1 (en) 2004-02-25
CN1507353A (zh) 2004-06-23
CA2446108A1 (en) 2002-11-21
WO2002092125A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
US20050031609A1 (en) Compositions for use in treating ige-associated disorders
JP2004529180A5 (enExample)
Scadding et al. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite
RU2587061C2 (ru) Способы лечения аллергических заболеваний
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
EP1322330B1 (en) Modulation of allergic response
KR20170044211A (ko) 항체 제제
US20080206237A1 (en) Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent
US6488937B1 (en) Allergy treatment method using a rapid immunotherapy protocol
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
NO144056B (no) Innretning for kunstig vanning av blomsterbed, hager etc.
US20060240000A1 (en) Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound
JPS63277634A (ja) アレルギーの治療およびそのための組成物
Cockcroft et al. Allergen injection therapy with glutaraldehyde-modified—ragweed pollen-tyrosine adsorbate: A double-blind trial
Pajnoª et al. Efficacy of Sublingual Immunotherapy in
US5135918A (en) Method for decreasing reaginic antibody levels
KR100723251B1 (ko) 알레르기 질환의 치료를 위한 약학적 조성물, 그의 용도 및알레르기 질환의 치료방법
EP1109557B1 (en) Use of cetirizine for preventing the onset of asthma
US7927600B2 (en) Anti-allergic pharmaceutical composition containing at least one allergen and at least one antihistamine compound
HK1066165A (en) Compositions for use in treating ige-associated disorders
JPWO2003020306A1 (ja) 脱感作剤
JP6664115B2 (ja) アフリベルセプトによる網膜保護作用
TW202110467A (zh) 眼用組成物及其在治療近視上的醫藥用途
Arabito et al. E Galli, MS Bassi, 2 E Mora, 3 M Martelli, 4 S Gianni, G Auricchio
Ghosh Immunotherapy in Children

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802